ARA-290: Evidence, Safety, Dosing and Access Questions

ARA-290, also called cibinetide, is an erythropoietin-derived peptide studied mainly in small-fiber neuropathy, including sarcoidosis-associated small nerve fiber loss. Its evidence grade is A because multiple human randomized controlled trials are indexed in PubMed, but that grade reflects study quantity and design—not proof that it works or is safe for every person 1 4 5. ARA-290 is discussed here as an investigational peptide; Chia does not offer it, and this article does not identify an FDA-approved ARA-290 product.

What it is

ARA-290, also called cibinetide, is a short peptide engineered from erythropoietin, a human signaling protein best known for its role in red-blood-cell production. In the ARA-290 literature, researchers describe it as a nonerythropoietic peptide, meaning it was designed to avoid the red-blood-cell-stimulating effect linked with erythropoietin while studying tissue-repair and nerve-related pathways 2.

The main human research area is small-fiber neuropathy, especially sarcoidosis-associated small nerve fiber loss. Human trials have studied neuropathic symptoms and corneal nerve fiber density, a research measure that can reflect small nerve fiber structure in the eye 1 4 5.

Names: ARA-290 and cibinetide

The names ARA-290 and cibinetide appear across the same research area. Earlier papers often use ARA 290, while later papers may use cibinetide; both names are tied to an erythropoietin-derived, nonerythropoietic peptide studied in nerve and repair models 2 5.

Main areas studied

• Sarcoidosis-associated small-fiber neuropathy and small nerve fiber loss in human randomized trials 1 4 5.
• Type 2 diabetes, metabolic control, and neuropathic symptoms in a human clinical trial 2.
• Human neuropsychological model testing for antidepressant-like properties, which should not be read as proof of routine depression treatment 3.
• Preclinical pain signaling, islet allograft, and wound-healing models, which are animal or laboratory findings and not proven patient outcomes 9 10 11.

Mechanism of action

ARA-290 is proposed to act through tissue-repair and nerve-signaling pathways linked with the innate repair receptor and the EPOR-β common receptor complex. The important limit is that receptor and pathway findings do not prove that a patient will have a clinical benefit 10 11 12.

The mechanism is often described as related to erythropoietin but not identical to erythropoietin’s red-blood-cell effect. A human type 2 diabetes study described ARA-290 as a nonerythropoietic peptide engineered from erythropoietin, while reviews discuss erythropoietin-derived peptides as a wider nerve-injury research area 2 12.

Preclinical work has also linked ARA-290 with the TRPV1 channel, a pain-signaling channel involved in nociception. That finding comes from non-human or laboratory research, so it should be viewed as a possible mechanism, not proof that ARA-290 is an established human pain treatment 9.

Animal studies have examined cibinetide in islet allograft function and diabetic wound-healing models. These studies help explain why researchers are interested in repair biology, but animal data do not show proven human benefit for diabetes complications, eye disease, wound healing, or longevity 10 11.

Evidence

ARA-290 has an assigned evidence grade of A — two or more human randomised controlled trials. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.

The strongest human evidence cluster is sarcoidosis-associated small nerve fiber loss. A randomized, double-blind pilot study tested ARA-290 in sarcoidosis patients with symptoms of small fiber neuropathy, and later randomized studies evaluated symptoms and corneal nerve fiber density 1 4 5.

The human diabetes literature is smaller. One clinical trial studied ARA-290 in people with type 2 diabetes and reported outcomes related to metabolic control and neuropathic symptoms, but one study is not enough to establish a general diabetes or weight-management role 2.

A separate randomized human neuropsychological model study tested antidepressant-like properties of ARA290. A model study can help researchers ask whether a signal is present, but it should not be treated as evidence that ARA-290 is an established depression treatment 3.

Reviews describe ARA-290 as an investigational approach in small-fiber neuropathy and place erythropoietin-derived peptides in a broader nerve-injury research field. Reviews are useful for context, but they do not replace larger, long-term human trials that can better measure uncommon harms and real-world outcomes 7 8 12.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-10.

Reported dosing ranges

ARA-290 dosing should not be copied from studies or online calculators. In the PubMed citation records supplied for this review, dosing details are not available in the citation strings, so we are not listing a personal-use dose or protocol.

This is intentional. Study dosing is chosen for a research question, a defined protocol, and a monitored group. It is not the same as a dose decision for a person with diabetes, neuropathy, eye disease, pregnancy, kidney or liver disease, or multiple medications.

Legal status

Our regulatory log holds no confirmed federal action for ARA-290. That means we have not found one with a primary source — not that none exists.

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-10. See the full legal-status tracker for every compound we follow.

Safety

ARA-290 safety data in humans are limited by trial size, study length, and selected study groups. A randomized pilot study in sarcoidosis was designed to assess safety and efficacy in people with small-fiber neuropathy symptoms, but small studies cannot rule out uncommon or delayed adverse effects 1.

The later sarcoidosis studies add human experience in small nerve fiber loss and neuropathic pain endpoints, including corneal nerve fiber abundance. Still, these trials do not prove safety for people outside the studied groups, such as people with different neuropathy causes, complex immune disease, pregnancy, or active eye disease 4 5.

The type 2 diabetes study is relevant because neuropathy and metabolic disease often overlap. But it does not establish that ARA-290 is safe for all people with diabetes, prediabetes, diabetic neuropathy, diabetic macular edema, or people using glucose-lowering medicines 2.

Preclinical studies in pain signaling, islet allograft function, and wound healing raise research questions but do not create a complete human safety profile. Animal and laboratory data cannot predict all human side effects, drug interactions, immune effects, or long-term outcomes 9 10 11.

Supply quality risks

For peptides in general, supply quality matters. A “research use only” vial is not the same thing as medication made for a person; the practical risks include wrong identity, wrong strength, impurities, contamination, poor sterility, and no clinical follow-up if side effects occur. The human ARA-290 studies cited here do not establish safety or quality for products sold outside monitored clinical or pharmacy pathways 1 2 4 5.

• Ask who is evaluating whether the peptide question fits your diagnosis and health history.
• Ask how identity, potency, sterility, and impurities are tested.
• Ask how side effects are reported and who follows up.
• Avoid treating online forum dosing or vendor marketing as medical guidance.

If your main question is whether to buy ARA-290 online, our deeper guide on buying ARA-290 peptide explains why clinician review and supply-chain quality matter more than speed or convenience.

Interactions

ARA-290 interaction studies are not established in the supplied human records. That is not reassurance; it means a licensed clinician would need to review medicines, supplements, diagnoses, pregnancy status, and the reason ARA-290 is being considered.

People with type 2 diabetes or neuropathy often take glucose-lowering medicines, pain medicines, antidepressants, blood-pressure drugs, supplements, or immune-related treatments. The ARA-290 diabetes and sarcoidosis studies do not provide enough information to treat these combinations as risk-free 1 2 4 5.

Eye disease is also important to disclose. ARA-290 research used corneal nerve fiber density or abundance as an endpoint in sarcoidosis-associated small nerve fiber loss, and a registered diabetic macular edema trial appears in the supplied trial list, but that does not make ARA-290 a proven eye-disease therapy 5.

• Tell a clinician about diabetes, prediabetes, neuropathy, sarcoidosis, immune disease, chronic pain, eye disease, kidney disease, liver disease, pregnancy, or plans for pregnancy.
• List all prescription drugs, over-the-counter medicines, peptides, hormones, and supplements.
• Ask how side effects would be tracked and what symptoms should prompt urgent care.
• Do not rely on an online interaction checker alone when the interaction literature is thin.

How to obtain it legally

ARA-290 questions should start with a licensed clinician, not a shopping cart. A proper process begins with your diagnosis, symptoms, medication list, health history, and the reason you are asking about a peptide.

When a prescription pathway is clinically appropriate for a medication, it generally includes a medical evaluation, a prescription from a licensed clinician, dispensing by a licensed pharmacy, clear labeling, adverse-event reporting, and follow-up. A research-chemical vendor does not replace those steps.

Chia does not offer ARA-290. We do publish peptide safety education because patients ask us about compounds they see online, including ARA-290, KPV, Semax, MOTS-c, and TB-500.

For treatments that Chia does offer, care is 100% online: a short health questionnaire, review by a licensed US provider, prescribing only where clinically appropriate, provider-guided dosing, portal messaging, and home delivery from state-licensed US 503A compounding pharmacies. A prescription is never guaranteed, and compounded drugs are not FDA-approved.

Questions to ask before using any peptide

• What diagnosis or treatment goal is being evaluated?
• What human evidence supports this use, and how strong is it?
• What side effects are known, and what is unknown?
• Who reviews my medication list and health history?
• Who makes the product, and what testing confirms identity, potency, sterility, and impurities?
• How do I report side effects, and who follows up?

Keep reading

Peptides

Can You Buy ARA-290 Peptide? What Patients Should Know First

Peptides

MOTS-c: Evidence, Safety, Dosing, and Access Questions

Peptides

MOTS-c Peptide Dosage Protocol: What Is Known and What Is Not